SCHEMBL3200519

SCHEMBL3200519

NC(=O)c1ccc(-c2ccc(O)cc2)n2n[c]nc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K1 Q02750 1/20 0.36
CLK4 Q9HAZ1 1/20 0.36
DYRK1B Q9Y463 1/20 0.36
PARP1 P09874 1/20 0.34
ESR1 P03372 1/20 0.34
ESR2 Q92731 1/20 0.34
NTRK1 P04629 5/20 0.34
PIM1 P11309 5/20 0.34
ACVR1 Q04771 2/20 0.34
MKNK1 Q9BUB5 2/20 0.34
MKNK2 Q9HBH9 2/20 0.34
CLK1 P49759 1/20 0.32
DYRK1A Q13627 1/20 0.32
AR P10275 1/20 0.31
CAPN1 P07384 1/20 0.31
CTSL P07711 1/20 0.31
CTSB P07858 1/20 0.31
CHUK O15111 1/20 0.31
TLR8 Q9NR97 2/20 0.30
KDM4E B2RXH2 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3601959 0.89 MAP2K1 (0.36) MAP2K1CLK4DYRK1BPARP1NTRK1
SCHEMBL2363030 0.88 NTRK1 (0.43) MAP2K1CLK4DYRK1BNTRK1PIM1
SCHEMBL3082604 0.87 MAP2K1 (0.49) MAP2K1CLK4DYRK1BPARP1NTRK1
SCHEMBL3262248 0.85 MAP2K1 (0.34) MAP2K1CLK4DYRK1BPARP1NTRK1
SCHEMBL2365481 0.85 MAP2K1 (0.34) MAP2K1CLK4DYRK1BNTRK1PIM1
SCHEMBL3090230 0.84 NTRK1 (0.47) PARP1NTRK1PIM1KDM4E
SCHEMBL3594492 0.84 NTRK1 (0.34) MAP2K1CLK4DYRK1BNTRK1PIM1
SCHEMBL2730821 0.84 MAP2K1 (0.34) MAP2K1CLK4DYRK1BNTRK1PIM1
SCHEMBL3098314 0.82 MKNK1 (0.35) MAP2K1CLK4DYRK1BNTRK1PIM1
SCHEMBL2362508 0.81 MAP2K1 (0.36) MAP2K1CLK4DYRK1BPARP1NTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10206907-B2 Compounds useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2019-02-19 US disclosed
US-20170035738-A1 NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES ALFASIGMA S.P.A. (IT) 2017-02-09 US disclosed
US-9415037-B2 Compounds useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2016-08-16 US disclosed
US-20150150856-A1 NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES ALFASIGMA S.P.A. (IT) 2015-06-04 US disclosed
US-8853240-B2 Compounds useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2014-10-07 US disclosed
EP-2361251-B1 NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS NV (BE) 2014-04-30 EP disclosed
EP-2346864-B1 NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES. GALAPAGOS NV (BE) 2013-03-06 EP disclosed
US-20120309784-A1 TRIAZOLOPYRIDINE KINASE INHIBITORS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS NV 2012-12-06 US disclosed
US-8242274-B2 Triazolopyridine kinase inhibitors useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2012-08-14 US disclosed
US-20100029709-A1 NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GILEAD SCIENCES, INC. 2010-02-04 US disclosed
WO-2010010190-A1 NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS NV (BE) 2010-01-28 WO disclosed
WO-2010010191-A1 NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES. GALAPAGOS NV (BE) 2010-01-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150150856-A1 NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES TLR6, TRAF6, BMP6 MAP2K1 2024/4885CLK4 2073/4885DYRK1B 3291/4885
US-10206907-B2 Compounds useful for the treatment of degenerative and inflammatory diseases TRAF6, TLR6, IL6 MAP2K1 2241/4885CLK4 2179/4885DYRK1B 3767/4885
US-20170035738-A1 NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES TLR6, TRAF6, BMP6 MAP2K1 2024/4885CLK4 2073/4885DYRK1B 3291/4885
US-20100029709-A1 NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES TRAF6, IL6, TLR6 MAP2K1 2002/4885CLK4 2140/4885DYRK1B 3329/4885
US-20120309784-A1 TRIAZOLOPYRIDINE KINASE INHIBITORS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GRK6, GRK4, GRK5 MAP2K1 224/4885CLK4 134/4885DYRK1B 995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.